Bank of America just raised its EUR/USD forecast
CAMBRIDGE, Mass. - Relay Therapeutics, Inc. (NASDAQ:RLAY) has appointed Claire Mazumdar, Ph.D., to its Board of Directors, effective June 9, the clinical-stage precision medicine company announced Wednesday.
Dr. Mazumdar currently serves as the founding Chief Executive Officer of Bicara Therapeutics (NASDAQ:BCAX), a clinical-stage oncology company. Her appointment comes as Relay prepares to initiate its Phase 3 ReDiscover-2 trial in breast cancer.
"It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics.
Before joining Bicara, Dr. Mazumdar led business development and corporate strategy at Rheos Medicines, where she supported the company’s global partnership with Roche Pharmaceuticals. Earlier in her career, she worked at Third Rock Ventures focusing on company formation and business development.
Dr. Mazumdar holds a B.S. in biological engineering from the Massachusetts Institute of Technology and earned both an MBA from Stanford Graduate School of Business and a Ph.D. in cancer biology from Stanford School of Medicine.
Relay Therapeutics combines computational and experimental technologies through its Dynamo® platform to address protein targets in oncology and genetic diseases that have previously been difficult to treat effectively.
This information is based on a press release statement from the company.
In other recent news, Bicara Therapeutics Inc has been the focus of several analyst updates following the release of promising clinical data. Stifel analysts have maintained their Buy rating on the company, setting a price target of $48.00. They expressed confidence in the ongoing clinical trials, particularly the combination of ficerafusp and pembrolizumab for treating squamous cell carcinoma of the head and neck (SCCHN). Cantor Fitzgerald analysts also reaffirmed an Overweight rating, emphasizing the potential of ficerafusp to achieve significant tumor shrinkage in over 80% of responders. These analysts noted a comparison with Merus NV, where fewer responders achieved similar results, underscoring Bicara’s potential efficacy.
The recent data from Bicara includes an improved complete response rate of 21% and a 12-month overall survival rate of 61% for HPV-negative patients. Despite these encouraging figures, the analysts advised caution in drawing competitive conclusions due to the complexity of small and non-randomized patient cohorts. Discussions at the American Society of Clinical Oncology (ASCO) meeting also highlighted the competitive landscape, with analysts suggesting that investors monitor future data releases. Both Stifel and Cantor Fitzgerald remain optimistic about Bicara’s prospects, citing the company’s commitment to advancing its clinical programs in oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.